SCHEMBL9963124

SCHEMBL9963124

Cc1nonc1C1CCCN1C(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ HDAC8 Q9BY41 1/20 0.38
▸ HDAC6 Q9UBN7 1/20 0.38
▸ MAPT P10636 1/20 0.36
▸ HTT P42858 1/20 0.36
▸ CLK1 P49759 1/20 0.35
▸ NPC1 O15118 2/20 0.34
▸ RAB9A P51151 2/20 0.34
▸ POLB P06746 1/20 0.33
▸ PARP1 P09874 3/20 0.33
▸ CHRNB2 P17787 1/20 0.33
▸ CHRNB4 P30926 1/20 0.33
▸ CHRNA3 P32297 1/20 0.33
▸ CHRNA7 P36544 1/20 0.33
▸ CHRNA4 P43681 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13629199 0.74 HDAC8 (0.40) ALDH1A1MEN1KMT2ANPSR1KDM4E
SCHEMBL23219805 0.73 CHRNB2 (0.35) MEN1KMT2ALMNAPOLBPARP1
SCHEMBL18997800 0.70 CHRNB2 (0.35) PARP1CHRNB2CHRNB4CHRNA3CHRNA7
SCHEMBL12890751 0.70 CHRM2 (0.43) HDAC8HDAC6
SCHEMBL18997799 0.69 EPHX2 (0.44) ALDH1A1KDM4ELMNAHTTCHRNB2
SCHEMBL14213477 0.68 OGA (0.37) ALDH1A1PARP1
SCHEMBL14213479 0.68 OGA (0.37) ALDH1A1PARP1
SCHEMBL14213466 0.68 OGA (0.37) ALDH1A1PARP1
SCHEMBL10094268 0.68 HDAC8 (0.43) ALDH1A1MEN1KMT2ANPSR1KDM4E
SCHEMBL9963155 0.66 HDAC6 (0.43) HDAC8HDAC6PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8354403-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2013-01-15 — — US disclosed
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME, CORP. (US) 2012-06-21 — — US disclosed
WO-2011025690-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2011-03-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 ALDH1A1 534/4885MEN1 4791/4885KMT2A 4265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback